Qum Therapeutics Develops immunotherapies that target pathogenic cells and engage the patient’s immune system to control disease.
Qymune has raised $10.0M in total funding. The most recent round was Seed. The last funding was announced in November 2025.
Qymune's investors include Sazze Partners, Nextrans, Primer, Mirae Asset Capital, Aju IB Investment.
Qymune is headquartered in San Francisco, United States.
Qum Therapeutics Develops immunotherapies that target pathogenic cells and engage the patient’s immune system to control disease.
Qymune is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Qymune — Funding & Investors." VCBacked, November 30, 2025, https://www.vcbacked.co/company/qymune. Accessed August 14, 2026.
VCBacked. (2025). Qymune — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/qymune
{{cite web |title=Qymune — Funding & Investors |url=https://www.vcbacked.co/company/qymune |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated